OptimizeRx (OPRX) Liabilities and Shareholders Equity (2016 - 2026)
OptimizeRx's Liabilities and Shareholders Equity history spans 16 years, with the latest figure at $176.9 million for Q4 2025.
- On a quarterly basis, Liabilities and Shareholders Equity rose 3.36% to $176.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $684.3 million, a 0.2% change, with the full-year FY2025 number at $176.9 million, up 3.36% from a year prior.
- Liabilities and Shareholders Equity hit $176.9 million in Q4 2025 for OptimizeRx, up from $170.3 million in the prior quarter.
- Over the last five years, Liabilities and Shareholders Equity for OPRX hit a ceiling of $183.4 million in Q4 2023 and a floor of $121.3 million in Q2 2023.
- Historically, Liabilities and Shareholders Equity has averaged $151.1 million across 5 years, with a median of $144.2 million in 2021.
- Biggest five-year swings in Liabilities and Shareholders Equity: surged 144.17% in 2021 and later dropped 17.72% in 2023.
- Tracing OPRX's Liabilities and Shareholders Equity over 5 years: stood at $141.0 million in 2021, then fell by 4.49% to $134.7 million in 2022, then surged by 36.18% to $183.4 million in 2023, then dropped by 6.66% to $171.2 million in 2024, then rose by 3.36% to $176.9 million in 2025.
- Business Quant data shows Liabilities and Shareholders Equity for OPRX at $176.9 million in Q4 2025, $170.3 million in Q3 2025, and $169.3 million in Q2 2025.